NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis $0.26 +0.01 (+2.50%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$0.26 -0.01 (-2.44%) As of 10/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Carisma Therapeutics Stock (NASDAQ:CARM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Carisma Therapeutics alerts:Sign Up Key Stats Today's Range$0.25▼$0.2750-Day Range$0.22▼$0.4452-Week Range$0.14▼$1.27Volume1.15 million shsAverage Volume1.24 million shsMarket Capitalization$10.97 millionP/E RatioN/ADividend YieldN/APrice Target$1.93Consensus RatingModerate Buy Company Overview Carisma Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells. The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies. Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.AI Generated. May Contain Errors. Read More Carisma Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreCARM MarketRank™: Carisma Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 572nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCarisma Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Upside PotentialCarisma Therapeutics has a consensus price target of $1.93, representing about 633.6% upside from its current price of $0.26.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Carisma Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Carisma Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.40% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Carisma Therapeutics has recently increased by 99.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.40% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Carisma Therapeutics has recently increased by 99.37%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment-0.43 News SentimentCarisma Therapeutics has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.Search Interest25 people have searched for CARM on MarketBeat in the last 30 days. This is an increase of 733% compared to the previous 30 days.MarketBeat Follows5 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,930.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Carisma Therapeutics is held by insiders.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Carisma Therapeutics' insider trading history. Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CARM Stock News HeadlinesCarisma Therapeutics (NASDAQ:CARM) Insider Michael Klichinsky Sells 119,347 SharesOctober 4, 2025 | insidertrades.comCarisma Therapeutics Inc. (NASDAQ:CARM) Receives Average Recommendation of "Moderate Buy" from Analysts1 hour ago | americanbankingnews.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed. | StockEarnings (Ad)Carisma Therapeutics Amends Agreement with ModernaSeptember 18, 2025 | tipranks.comCarisma Therapeutics Approves Reverse Stock SplitAugust 20, 2025 | theglobeandmail.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - MorningstarJuly 5, 2025 | morningstar.comMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, CARM, ENZB on Behalf of ShareholdersJuly 5, 2025 | globenewswire.comCarisma Therapeutics Inc News (CARM) - Investing.comJuly 3, 2025 | investing.comSee More Headlines CARM Stock Analysis - Frequently Asked Questions How have CARM shares performed this year? Carisma Therapeutics' stock was trading at $0.4188 at the start of the year. Since then, CARM stock has decreased by 37.3% and is now trading at $0.2624. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics Inc. (NASDAQ:CARM) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.05. The company earned $3.65 million during the quarter, compared to analyst estimates of $2.47 million. How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Carisma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/13/2025Today10/07/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARM CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911Employees20Year Founded2016Price Target and Rating Average Price Target for Carisma Therapeutics$1.93 High Price Target$5.00 Low Price Target$0.70 Potential Upside/Downside+633.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.48 million Net Margins-254.28% Pretax Margin-458.60% Return on EquityN/A Return on Assets-192.17% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$10.77 million Price / Sales1.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-0.39Miscellaneous Outstanding Shares41,788,000Free Float38,905,000Market Cap$10.97 million OptionableNo Data Beta2.06 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CARM) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.